"Using the Iverson Warfarin Dosing Panel has, in my opinion, had an immediate impact on the patients in our cardiovascular and thoracic surgery practice. Of our patients requiring long-term anticoagulation, we are able to get our patients to an INR goal more quickly and more reliably than with standard titration regimens, thereby decreasing their risks of life-threatening complications of supratherapeutic and subtherapeutic levels. With respect to our older population, who are frequently on multiple medicines, there is no question that they benefit from tighter control and lack of the need to keep up with different doses on different days of the week, which frequently happens with current dosing techniques."
Victor A. Gomez, PA-C
Chief Physician Assistant, Cardiothoracic & Vascular Surgery
"Warfarin has a misnomer among healthcare workers that some people are too high risk to take Coumadin (Warfarin). What contributes to this misnomer is that Coumadin is very challenging to regulate. Since our office started using Iverson's Warfarin genetic test we have a better dosing for our patients and now have removed the guesswork involved with proper dosing.
With the Iverson genetic test we have figured out who is hypersensitive and who is not and we are able to dose patients properly so that their INRs do not have such a large range. Also, making this drug safer to use on patients who in the past were deemed unsafe to use, we are now actually putting them on Warfarin and helping to lower their risk of stroke in high-risk atrial fibrillation patients. Knowing how to dose Warfarin can be difficult, but with genetic testing we can get patients safely into therapeutic range.
We no longer fear overshooting a patient's INR goal. If you know a patient's therapeutic dose 24 hours after genetic testing, then often you can get patients to a stable INR within 2 weeks, as opposed to the trial and error method without genetic testing that requires 6 weeks or more."
Craig J. McCotter, M.D., F.A.C.C
Upstate Cardiology
|
|
|
